永井 純正

最終更新日時: 2021/09/22 15:30:37

印刷する

氏名(漢字/フリガナ/アルファベット表記)
永井 純正/ナガイ スミマサ/Nagai, Sumimasa
所属部署・職名(部局/所属/講座等/職名)
医学部附属病院/先端医療研究開発機構/教授
取得学位
学位名(日本語) 学位名(英語) 大学(日本語) 大学(英語) 取得区分
博士(医学) 東京大学
researchmap URL
https://researchmap.jp/sunagai
論文
著者 著者(日本語) 著者(英語) タイトル タイトル(日本語) タイトル(英語) 書誌情報等 書誌情報等(日本語) 書誌情報等(英語) 出版年月 査読の有無 記述言語 掲載種別 公開
Sumimasa Nagai Sumimasa Nagai Sumimasa Nagai Regulatory hurdles for CAR T-cell therapy in Japan Regulatory hurdles for CAR T-cell therapy in Japan Regulatory hurdles for CAR T-cell therapy in Japan The Lancet Haematology, 8, 10, e686-e687 The Lancet Haematology, 8, 10, e686-e687 The Lancet Haematology, 8, 10, e686-e687 2021/10 英語 公開
Sumimasa Nagai Sumimasa Nagai Sumimasa Nagai Current situation of oncology biosimilars in Japan. Current situation of oncology biosimilars in Japan. Current situation of oncology biosimilars in Japan. The Lancet Oncology, 22, 3, e82 The Lancet Oncology, 22, 3, e82 The Lancet Oncology, 22, 3, e82 2021/03 英語 公開
Charles L Bennett, Sumimasa Nagai, Andrew C Bennett, Shamia Hoque, Chadi Nabhan, Martin W Schoen, William J Hrushesky, Stefano Luminari, Paul Ray, Paul R Yarnold, Bart Witherspoon, Josh Riente, Laura Bobolts, John Brusk, Rebecca Tombleson, Kevin Knopf, Marc Fishman, Y Tony Yang, Kenneth R Carson, Benjamin Djulbegovic, John Restaino, James O Armitage, Oliver A Sartor Charles L Bennett, Sumimasa Nagai, Andrew C Bennett, Shamia Hoque, Chadi Nabhan, Martin W Schoen, William J Hrushesky, Stefano Luminari, Paul Ray, Paul R Yarnold, Bart Witherspoon, Josh Riente, Laura Bobolts, John Brusk, Rebecca Tombleson, Kevin Knopf, Marc Fishman, Y Tony Yang, Kenneth R Carson, Benjamin Djulbegovic, John Restaino, James O Armitage, Oliver A Sartor Charles L Bennett, Sumimasa Nagai, Andrew C Bennett, Shamia Hoque, Chadi Nabhan, Martin W Schoen, William J Hrushesky, Stefano Luminari, Paul Ray, Paul R Yarnold, Bart Witherspoon, Josh Riente, Laura Bobolts, John Brusk, Rebecca Tombleson, Kevin Knopf, Marc Fishman, Y Tony Yang, Kenneth R Carson, Benjamin Djulbegovic, John Restaino, James O Armitage, Oliver A Sartor The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions. The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions. The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions. The oncologist The oncologist The oncologist 2021/02/14 英語 公開
Sumimasa Nagai Sumimasa Nagai Sumimasa Nagai Flexible and Expedited Regulatory Review Processes for Innovative Medicines and Regenerative Medical Products in the US, the EU, and Japan. Flexible and Expedited Regulatory Review Processes for Innovative Medicines and Regenerative Medical Products in the US, the EU, and Japan. Flexible and Expedited Regulatory Review Processes for Innovative Medicines and Regenerative Medical Products in the US, the EU, and Japan. International journal of molecular sciences, 20, 15 International journal of molecular sciences, 20, 15 International journal of molecular sciences, 20, 15 2019/08/03 英語 公開
Roberto Salgado, David B Solit, David L Rimm, Jan Bogaerts, Renzo Canetta, Tracy Lively, Kim Lyerly, Paul N Span, Alison Bateman-House, Amr Makady, L Bergmann, Sumimasa Nagai, Chris Smith, Mark Robson, Mary Savage, Emile Voest, Christopher Sweeney, Philippe Lambin, Marlene Thomas, Lyndsay Harris, Denis Lacombe, Chistophe Massard Roberto Salgado, David B Solit, David L Rimm, Jan Bogaerts, Renzo Canetta, Tracy Lively, Kim Lyerly, Paul N Span, Alison Bateman-House, Amr Makady, L Bergmann, Sumimasa Nagai, Chris Smith, Mark Robson, Mary Savage, Emile Voest, Christopher Sweeney, Philippe Lambin, Marlene Thomas, Lyndsay Harris, Denis Lacombe, Chistophe Massard Roberto Salgado, David B Solit, David L Rimm, Jan Bogaerts, Renzo Canetta, Tracy Lively, Kim Lyerly, Paul N Span, Alison Bateman-House, Amr Makady, L Bergmann, Sumimasa Nagai, Chris Smith, Mark Robson, Mary Savage, Emile Voest, Christopher Sweeney, Philippe Lambin, Marlene Thomas, Lyndsay Harris, Denis Lacombe, Chistophe Massard Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology. Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology. Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology. European journal of cancer (Oxford, England : 1990), 114, 128-136 European journal of cancer (Oxford, England : 1990), 114, 128-136 European journal of cancer (Oxford, England : 1990), 114, 128-136 2019/06 英語 公開
Brian Chen, Sumimasa Nagai, James O Armitage, Bartlett Witherspoon, Chadi Nabhan, Ashley C Godwin, Y Tony Yang, Anuhya Kommalapati, Sri Harsha Tella, Carlo DeAngelis, Dennis W Raisch, Oliver Sartor, William J Hrushesky, Paul S Ray, Paul R Yarnold, Bryan L Love, LeAnn B Norris, Kevin Knopf, Laura Bobolts, Joshua Riente, Stefano Luminari, Robert C Kane, Shamia Hoque, Charles L Bennett Brian Chen, Sumimasa Nagai, James O Armitage, Bartlett Witherspoon, Chadi Nabhan, Ashley C Godwin, Y Tony Yang, Anuhya Kommalapati, Sri Harsha Tella, Carlo DeAngelis, Dennis W Raisch, Oliver Sartor, William J Hrushesky, Paul S Ray, Paul R Yarnold, Bryan L Love, LeAnn B Norris, Kevin Knopf, Laura Bobolts, Joshua Riente, Stefano Luminari, Robert C Kane, Shamia Hoque, Charles L Bennett Brian Chen, Sumimasa Nagai, James O Armitage, Bartlett Witherspoon, Chadi Nabhan, Ashley C Godwin, Y Tony Yang, Anuhya Kommalapati, Sri Harsha Tella, Carlo DeAngelis, Dennis W Raisch, Oliver Sartor, William J Hrushesky, Paul S Ray, Paul R Yarnold, Bryan L Love, LeAnn B Norris, Kevin Knopf, Laura Bobolts, Joshua Riente, Stefano Luminari, Robert C Kane, Shamia Hoque, Charles L Bennett Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada. Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada. Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada. The oncologist, 24, 4, 537-548 The oncologist, 24, 4, 537-548 The oncologist, 24, 4, 537-548 2019/04 英語 公開
Zaina P Qureshi, Sumimasa Nagai, Charles L Bennett Zaina P Qureshi, Sumimasa Nagai, Charles L Bennett Zaina P Qureshi, Sumimasa Nagai, Charles L Bennett Biosimilar Filgrastim Use in the United States vs the European Union and Japan-Why Does It Lag Behind and What Can Be Done? Biosimilar Filgrastim Use in the United States vs the European Union and Japan-Why Does It Lag Behind and What Can Be Done? Biosimilar Filgrastim Use in the United States vs the European Union and Japan-Why Does It Lag Behind and What Can Be Done? JAMA oncology, 5, 3, 297-298 JAMA oncology, 5, 3, 297-298 JAMA oncology, 5, 3, 297-298 2019/03/01 英語 公開
Sumimasa Nagai, Daisuke Sugiyama Sumimasa Nagai, Daisuke Sugiyama Sumimasa Nagai, Daisuke Sugiyama Current Trends in Clinical Development of Gene and Cellular Therapeutic Products for Cancer in Japan. Current Trends in Clinical Development of Gene and Cellular Therapeutic Products for Cancer in Japan. Current Trends in Clinical Development of Gene and Cellular Therapeutic Products for Cancer in Japan. Clinical therapeutics, 41, 1, 174-184 Clinical therapeutics, 41, 1, 174-184 Clinical therapeutics, 41, 1, 174-184 2019/01 英語 公開
H Kim Lyerly, Jun Ren, Renzo Canetta, Gi Hyun Kim, Sumimasa Nagai, Tomohiro Yamaguchi, Ken Hatogai, Hiroshi Katayama, Silvy Da Rocha Dias, Daniel McManus, Kathy Soltys, Zhimin Yang, Olufumilayo Olopade, Nancy Goodman, Greg Reaman, Thomas Gross H Kim Lyerly, Jun Ren, Renzo Canetta, Gi Hyun Kim, Sumimasa Nagai, Tomohiro Yamaguchi, Ken Hatogai, Hiroshi Katayama, Silvy Da Rocha Dias, Daniel McManus, Kathy Soltys, Zhimin Yang, Olufumilayo Olopade, Nancy Goodman, Greg Reaman, Thomas Gross H Kim Lyerly, Jun Ren, Renzo Canetta, Gi Hyun Kim, Sumimasa Nagai, Tomohiro Yamaguchi, Ken Hatogai, Hiroshi Katayama, Silvy Da Rocha Dias, Daniel McManus, Kathy Soltys, Zhimin Yang, Olufumilayo Olopade, Nancy Goodman, Greg Reaman, Thomas Gross Global Development of Anticancer Therapies for Rare Cancers, Pediatric Cancers, and Molecular Subtypes of Common Cancers. Global Development of Anticancer Therapies for Rare Cancers, Pediatric Cancers, and Molecular Subtypes of Common Cancers. Global Development of Anticancer Therapies for Rare Cancers, Pediatric Cancers, and Molecular Subtypes of Common Cancers. Journal of global oncology, 4, 1-11 Journal of global oncology, 4, 1-11 Journal of global oncology, 4, 1-11 2018/12 英語 公開
Gita Thanarajasingam, Lori M Minasian, Frederic Baron, Franco Cavalli, R Angelo De Claro, Amylou C Dueck, Tarec C El-Galaly, Neil Everest, Jan Geissler, Christian Gisselbrecht, John Gribben, Mary Horowitz, S Percy Ivy, Caron A Jacobson, Armand Keating, Paul G Kluetz, Aviva Krauss, Yok Lam Kwong, Richard F Little, Francois-Xavier Mahon, Matthew J Matasar, María-Victoria Mateos, Kristen McCullough, Robert S Miller, Mohamad Mohty, Philippe Moreau, Lindsay M Morton, Sumimasa Nagai, Simon Rule, Jeff Sloan, Pieter Sonneveld, Carrie A Thompson, Kyriaki Tzogani, Flora E van Leeuwen, Galina Velikova, Diego Villa, John R Wingard, Sophie Wintrich, John F Seymour, Thomas M Habermann Gita Thanarajasingam, Lori M Minasian, Frederic Baron, Franco Cavalli, R Angelo De Claro, Amylou C Dueck, Tarec C El-Galaly, Neil Everest, Jan Geissler, Christian Gisselbrecht, John Gribben, Mary Horowitz, S Percy Ivy, Caron A Jacobson, Armand Keating, Paul G Kluetz, Aviva Krauss, Yok Lam Kwong, Richard F Little, Francois-Xavier Mahon, Matthew J Matasar, María-Victoria Mateos, Kristen McCullough, Robert S Miller, Mohamad Mohty, Philippe Moreau, Lindsay M Morton, Sumimasa Nagai, Simon Rule, Jeff Sloan, Pieter Sonneveld, Carrie A Thompson, Kyriaki Tzogani, Flora E van Leeuwen, Galina Velikova, Diego Villa, John R Wingard, Sophie Wintrich, John F Seymour, Thomas M Habermann Gita Thanarajasingam, Lori M Minasian, Frederic Baron, Franco Cavalli, R Angelo De Claro, Amylou C Dueck, Tarec C El-Galaly, Neil Everest, Jan Geissler, Christian Gisselbrecht, John Gribben, Mary Horowitz, S Percy Ivy, Caron A Jacobson, Armand Keating, Paul G Kluetz, Aviva Krauss, Yok Lam Kwong, Richard F Little, Francois-Xavier Mahon, Matthew J Matasar, María-Victoria Mateos, Kristen McCullough, Robert S Miller, Mohamad Mohty, Philippe Moreau, Lindsay M Morton, Sumimasa Nagai, Simon Rule, Jeff Sloan, Pieter Sonneveld, Carrie A Thompson, Kyriaki Tzogani, Flora E van Leeuwen, Galina Velikova, Diego Villa, John R Wingard, Sophie Wintrich, John F Seymour, Thomas M Habermann Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. The Lancet Haematology, 5, 11, e563-e598 The Lancet Haematology, 5, 11, e563-e598 The Lancet Haematology, 5, 11, e563-e598 2018/11 英語 公開
Sumimasa Nagai, Keiya Ozawa Sumimasa Nagai, Keiya Ozawa Sumimasa Nagai, Keiya Ozawa Drug approval based on randomized phase 3 trials for relapsed malignancy: analysis of oncologic drugs granted accelerated approval, publications and clinical trial databases. Drug approval based on randomized phase 3 trials for relapsed malignancy: analysis of oncologic drugs granted accelerated approval, publications and clinical trial databases. Drug approval based on randomized phase 3 trials for relapsed malignancy: analysis of oncologic drugs granted accelerated approval, publications and clinical trial databases. Investigational new drugs, 36, 3, 487-495 Investigational new drugs, 36, 3, 487-495 Investigational new drugs, 36, 3, 487-495 2018/06 英語 公開
Roberto Salgado, on behalf of, Helen Moore, John W.M. Martens, Tracy Lively, Shakun Malik, Ultan McDermott, Stefan Michiels, Jeffrey A. Moscow, Sabine Tejpar, Tawnya McKee, Denis Lacombe, Robert Becker, Philip Beer, Jonas Bergh, Jan Bogaerts, Simon Dovedi, Antonio T. Fojo, Moritz Gerstung, Vassilis Golfinopoulos, Stephen Hewitt, Daniel Hochhauser, Hartmut Juhl, Robert Kinders, Thomas Lillie, Kim Lyerly Herbert, Shyamala Maheswaran, Mehdi Mesri, Sumimasa Nagai, Irene Norstedt, Daniel O'Connor, Kathy Oliver, Wim J.G. Oyen, Francesco Pignatti, Eric Polley, Nitzan Rosenfeld, Jan Schellens, Richard Schilsky, Erasmus Schneider, Adrian Senderowicz, Olli Tenhunen, Augustinus van Dongen, Christine Vietz, Nils Wilking Roberto Salgado, on behalf of, Helen Moore, John W.M. Martens, Tracy Lively, Shakun Malik, Ultan McDermott, Stefan Michiels, Jeffrey A. Moscow, Sabine Tejpar, Tawnya McKee, Denis Lacombe, Robert Becker, Philip Beer, Jonas Bergh, Jan Bogaerts, Simon Dovedi, Antonio T. Fojo, Moritz Gerstung, Vassilis Golfinopoulos, Stephen Hewitt, Daniel Hochhauser, Hartmut Juhl, Robert Kinders, Thomas Lillie, Kim Lyerly Herbert, Shyamala Maheswaran, Mehdi Mesri, Sumimasa Nagai, Irene Norstedt, Daniel O'Connor, Kathy Oliver, Wim J.G. Oyen, Francesco Pignatti, Eric Polley, Nitzan Rosenfeld, Jan Schellens, Richard Schilsky, Erasmus Schneider, Adrian Senderowicz, Olli Tenhunen, Augustinus van Dongen, Christine Vietz, Nils Wilking Roberto Salgado, on behalf of, Helen Moore, John W.M. Martens, Tracy Lively, Shakun Malik, Ultan McDermott, Stefan Michiels, Jeffrey A. Moscow, Sabine Tejpar, Tawnya McKee, Denis Lacombe, Robert Becker, Philip Beer, Jonas Bergh, Jan Bogaerts, Simon Dovedi, Antonio T. Fojo, Moritz Gerstung, Vassilis Golfinopoulos, Stephen Hewitt, Daniel Hochhauser, Hartmut Juhl, Robert Kinders, Thomas Lillie, Kim Lyerly Herbert, Shyamala Maheswaran, Mehdi Mesri, Sumimasa Nagai, Irene Norstedt, Daniel O'Connor, Kathy Oliver, Wim J.G. Oyen, Francesco Pignatti, Eric Polley, Nitzan Rosenfeld, Jan Schellens, Richard Schilsky, Erasmus Schneider, Adrian Senderowicz, Olli Tenhunen, Augustinus van Dongen, Christine Vietz, Nils Wilking Societal challenges of precision medicine: Bringing order to chaos Societal challenges of precision medicine: Bringing order to chaos Societal challenges of precision medicine: Bringing order to chaos European Journal of Cancer, 84, 325-334 European Journal of Cancer, 84, 325-334 European Journal of Cancer, 84, 325-334 2017/10/01 英語 公開
Charles L Bennett, Sumimasa Nagai, Y Tony Yang, Brian K Chen, Oliver Sartor, James O Armitage Charles L Bennett, Sumimasa Nagai, Y Tony Yang, Brian K Chen, Oliver Sartor, James O Armitage Charles L Bennett, Sumimasa Nagai, Y Tony Yang, Brian K Chen, Oliver Sartor, James O Armitage Generic drugs in oncology - Authors' reply. Generic drugs in oncology - Authors' reply. Generic drugs in oncology - Authors' reply. The Lancet Oncology, 18, 2, e64 The Lancet Oncology, 18, 2, e64 The Lancet Oncology, 18, 2, e64 2017/02 英語 公開
Sumimasa Nagai, Keiya Ozawa Sumimasa Nagai, Keiya Ozawa Sumimasa Nagai, Keiya Ozawa New Japanese Regulatory Frameworks for Clinical Research and Marketing Authorization of Gene Therapy and Cellular Therapy Products. New Japanese Regulatory Frameworks for Clinical Research and Marketing Authorization of Gene Therapy and Cellular Therapy Products. New Japanese Regulatory Frameworks for Clinical Research and Marketing Authorization of Gene Therapy and Cellular Therapy Products. Current gene therapy, 17, 1, 17-28 Current gene therapy, 17, 1, 17-28 Current gene therapy, 17, 1, 17-28 2017 英語 公開
Sumimasa Nagai, Keiya Ozawa Sumimasa Nagai, Keiya Ozawa Sumimasa Nagai, Keiya Ozawa Comprehensive analysis of clinical development and regulatory submission promotion schemes for oncologic drugs as the Japanese national projects. Comprehensive analysis of clinical development and regulatory submission promotion schemes for oncologic drugs as the Japanese national projects. Comprehensive analysis of clinical development and regulatory submission promotion schemes for oncologic drugs as the Japanese national projects. Investigational new drugs, 34, 6, 777-791 Investigational new drugs, 34, 6, 777-791 Investigational new drugs, 34, 6, 777-791 2016/12 英語 公開
Y Tony Yang, Sumimasa Nagai, Brian K Chen, Zaina P Qureshi, Akida A Lebby, Samuel Kessler, Peter Georgantopoulos, Dennis W Raisch, Oliver Sartor, Terhi Hermanson, Robert C Kane, William J Hrushesky, Joshua J Riente, LeAnn B Norris, Laura R Bobolts, James O Armitage, Charles L Bennett Y Tony Yang, Sumimasa Nagai, Brian K Chen, Zaina P Qureshi, Akida A Lebby, Samuel Kessler, Peter Georgantopoulos, Dennis W Raisch, Oliver Sartor, Terhi Hermanson, Robert C Kane, William J Hrushesky, Joshua J Riente, LeAnn B Norris, Laura R Bobolts, James O Armitage, Charles L Bennett Y Tony Yang, Sumimasa Nagai, Brian K Chen, Zaina P Qureshi, Akida A Lebby, Samuel Kessler, Peter Georgantopoulos, Dennis W Raisch, Oliver Sartor, Terhi Hermanson, Robert C Kane, William J Hrushesky, Joshua J Riente, LeAnn B Norris, Laura R Bobolts, James O Armitage, Charles L Bennett Generic oncology drugs: are they all safe? Generic oncology drugs: are they all safe? Generic oncology drugs: are they all safe? The Lancet Oncology, 17, 11, e493-e501 The Lancet Oncology, 17, 11, e493-e501 The Lancet Oncology, 17, 11, e493-e501 2016/11 英語 公開
Sumimasa Nagai, Keiya Ozawa Sumimasa Nagai, Keiya Ozawa Sumimasa Nagai, Keiya Ozawa Clinical trial designs to obtain marketing authorization of drugs for haematological malignancy in Japan, the EU and the US. Clinical trial designs to obtain marketing authorization of drugs for haematological malignancy in Japan, the EU and the US. Clinical trial designs to obtain marketing authorization of drugs for haematological malignancy in Japan, the EU and the US. British journal of haematology, 174, 2, 249-54 British journal of haematology, 174, 2, 249-54 British journal of haematology, 174, 2, 249-54 2016/07 英語 公開
Sumimasa Nagai, Keiya Ozawa Sumimasa Nagai, Keiya Ozawa Sumimasa Nagai, Keiya Ozawa Regulatory approval pathways for anticancer drugs in Japan, the EU and the US. Regulatory approval pathways for anticancer drugs in Japan, the EU and the US. Regulatory approval pathways for anticancer drugs in Japan, the EU and the US. International journal of hematology, 104, 1, 73-84 International journal of hematology, 104, 1, 73-84 International journal of hematology, 104, 1, 73-84 2016/07 英語 公開
Sumimasa Nagai, Masaaki Urata, Hiroyuki Sato, Motoki Mikami, Wataru Kuga, Reiko Yanagihara, Daisei Miyamoto, Yuka Suzuki, Mayumi Shikano Sumimasa Nagai, Masaaki Urata, Hiroyuki Sato, Motoki Mikami, Wataru Kuga, Reiko Yanagihara, Daisei Miyamoto, Yuka Suzuki, Mayumi Shikano Sumimasa Nagai, Masaaki Urata, Hiroyuki Sato, Motoki Mikami, Wataru Kuga, Reiko Yanagihara, Daisei Miyamoto, Yuka Suzuki, Mayumi Shikano Evolving Japanese regulations on companion diagnostics. Evolving Japanese regulations on companion diagnostics. Evolving Japanese regulations on companion diagnostics. Nature biotechnology, 34, 2, 141-4 Nature biotechnology, 34, 2, 141-4 Nature biotechnology, 34, 2, 141-4 2016/02 英語 公開
Sumimasa Nagai, Reiko Yanagihara, Yasuhiro Kishioka Sumimasa Nagai, Reiko Yanagihara, Yasuhiro Kishioka Sumimasa Nagai, Reiko Yanagihara, Yasuhiro Kishioka Japanese regulatory authority's perspective on biosimilars. Japanese regulatory authority's perspective on biosimilars. Japanese regulatory authority's perspective on biosimilars. The Lancet Oncology, 16, 3, e101 The Lancet Oncology, 16, 3, e101 The Lancet Oncology, 16, 3, e101 2015/03 英語 公開
Sumimasa Nagai Sumimasa Nagai Sumimasa Nagai [Exploratory biomarker analyses and companion diagnostics]. [Exploratory biomarker analyses and companion diagnostics]. [Exploratory biomarker analyses and companion diagnostics]. Nihon rinsho. Japanese journal of clinical medicine, 73 Suppl 2, 126-30 Nihon rinsho. Japanese journal of clinical medicine, 73 Suppl 2, 126-30 Nihon rinsho. Japanese journal of clinical medicine, 73 Suppl 2, 126-30 2015/02 日本語 公開
Sumimasa Nagai, Tsuyoshi Takahashi, Mineo Kurokawa Sumimasa Nagai, Tsuyoshi Takahashi, Mineo Kurokawa Sumimasa Nagai, Tsuyoshi Takahashi, Mineo Kurokawa The impact of molecularly targeted therapies upon the understanding of leukemogenesis and the role of hematopoietic stem cell transplantation in acute promyelocytic leukemia. The impact of molecularly targeted therapies upon the understanding of leukemogenesis and the role of hematopoietic stem cell transplantation in acute promyelocytic leukemia. The impact of molecularly targeted therapies upon the understanding of leukemogenesis and the role of hematopoietic stem cell transplantation in acute promyelocytic leukemia. Current stem cell research & therapy, 5, 4, 372-8 Current stem cell research & therapy, 5, 4, 372-8 Current stem cell research & therapy, 5, 4, 372-8 2010/12 英語 公開
Sumimasa Nagai, Yasuhito Nannya, Tsuyoshi Takahashi, Mineo Kurokawa Sumimasa Nagai, Yasuhito Nannya, Tsuyoshi Takahashi, Mineo Kurokawa Sumimasa Nagai, Yasuhito Nannya, Tsuyoshi Takahashi, Mineo Kurokawa Jumping translocation involving 1q21 during long-term complete remission of acute myeloid leukemia. Jumping translocation involving 1q21 during long-term complete remission of acute myeloid leukemia. Jumping translocation involving 1q21 during long-term complete remission of acute myeloid leukemia. Annals of hematology, 89, 7, 741-2 Annals of hematology, 89, 7, 741-2 Annals of hematology, 89, 7, 741-2 2010/07 英語 公開
Sumimasa Nagai, Tsuyoshi Takahashi, Mineo Kurokawa Sumimasa Nagai, Tsuyoshi Takahashi, Mineo Kurokawa Sumimasa Nagai, Tsuyoshi Takahashi, Mineo Kurokawa How should we prevent hematologic relapse of acute promyelocytic leukemia? How should we prevent hematologic relapse of acute promyelocytic leukemia? How should we prevent hematologic relapse of acute promyelocytic leukemia? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28, 4, e62; author reply e63-4 Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28, 4, e62; author reply e63-4 Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28, 4, e62; author reply e63-4 2010/02/01 英語 公開
Sumimasa Nagai, Tsuyoshi Takahashi, Mineo Kurokawa Sumimasa Nagai, Tsuyoshi Takahashi, Mineo Kurokawa Sumimasa Nagai, Tsuyoshi Takahashi, Mineo Kurokawa Risk-adapted maintenance therapy for acute promyelocytic leukemia. Risk-adapted maintenance therapy for acute promyelocytic leukemia. Risk-adapted maintenance therapy for acute promyelocytic leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28, 2, e21; author reply e22-3 Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28, 2, e21; author reply e22-3 Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28, 2, e21; author reply e22-3 2010/01/10 英語 公開
Koki Ueda, Sumimasa Nagai, Shin-ich Miyashita, Toshikazu Kaise, Motoshi Ichikawa, Keiki Kumano, Akira Hangaishi, Yasuhito Nannya, Mineo Kurokawa Koki Ueda, Sumimasa Nagai, Shin-ich Miyashita, Toshikazu Kaise, Motoshi Ichikawa, Keiki Kumano, Akira Hangaishi, Yasuhito Nannya, Mineo Kurokawa Koki Ueda, Sumimasa Nagai, Shin-ich Miyashita, Toshikazu Kaise, Motoshi Ichikawa, Keiki Kumano, Akira Hangaishi, Yasuhito Nannya, Mineo Kurokawa Arsenic-induced pericardial and pleural effusion without acute promyelocytic leukemia differentiation syndrome. Arsenic-induced pericardial and pleural effusion without acute promyelocytic leukemia differentiation syndrome. Arsenic-induced pericardial and pleural effusion without acute promyelocytic leukemia differentiation syndrome. Leukemia research, 34, 1, e25-6 Leukemia research, 34, 1, e25-6 Leukemia research, 34, 1, e25-6 2010/01 英語 公開
Sumimasa Nagai, Yasuhito Nannya, Shunya Arai, Yumiko Yoshiki, Tsuyoshi Takahashi, Mineo Kurokawa Sumimasa Nagai, Yasuhito Nannya, Shunya Arai, Yumiko Yoshiki, Tsuyoshi Takahashi, Mineo Kurokawa Sumimasa Nagai, Yasuhito Nannya, Shunya Arai, Yumiko Yoshiki, Tsuyoshi Takahashi, Mineo Kurokawa Molecular or cytogenetic monitoring and preemptive therapy for central nervous system relapse of acute promyelocytic leukemia. Molecular or cytogenetic monitoring and preemptive therapy for central nervous system relapse of acute promyelocytic leukemia. Molecular or cytogenetic monitoring and preemptive therapy for central nervous system relapse of acute promyelocytic leukemia. Haematologica, 95, 1, 169-71 Haematologica, 95, 1, 169-71 Haematologica, 95, 1, 169-71 2010/01 英語 公開
Sumimasa Nagai, Tsuyoshi Takahashi, Mineo Kurokawa Sumimasa Nagai, Tsuyoshi Takahashi, Mineo Kurokawa Sumimasa Nagai, Tsuyoshi Takahashi, Mineo Kurokawa Beneficial and adverse effects of molecularly targeted therapies for acute promyelocytic leukemia in central nervous system. Beneficial and adverse effects of molecularly targeted therapies for acute promyelocytic leukemia in central nervous system. Beneficial and adverse effects of molecularly targeted therapies for acute promyelocytic leukemia in central nervous system. CNS & neurological disorders drug targets, 8, 5, 387-92 CNS & neurological disorders drug targets, 8, 5, 387-92 CNS & neurological disorders drug targets, 8, 5, 387-92 2009/11 英語 公開
Sumimasa Nagai, Yasuhito Nannya, Akira Hangaishi, Tsuyoshi Takahashi, Mineo Kurokawa Sumimasa Nagai, Yasuhito Nannya, Akira Hangaishi, Tsuyoshi Takahashi, Mineo Kurokawa Sumimasa Nagai, Yasuhito Nannya, Akira Hangaishi, Tsuyoshi Takahashi, Mineo Kurokawa The race and dose of chemotherapy should be considered for optimizing maintenance therapy for acute promyelocytic leukemia. The race and dose of chemotherapy should be considered for optimizing maintenance therapy for acute promyelocytic leukemia. The race and dose of chemotherapy should be considered for optimizing maintenance therapy for acute promyelocytic leukemia. Leukemia research, 33, 10, 1427-9 Leukemia research, 33, 10, 1427-9 Leukemia research, 33, 10, 1427-9 2009/10 英語 公開
Sumimasa Nagai, Koji Izutsu, Takuro Watanabe, Mineo Kurokawa Sumimasa Nagai, Koji Izutsu, Takuro Watanabe, Mineo Kurokawa Sumimasa Nagai, Koji Izutsu, Takuro Watanabe, Mineo Kurokawa Simultaneous appearance of methotrexate-associated lymphoproliferative disorder and tuberculous meningitis demonstrating the definitive role of immunosuppression. Simultaneous appearance of methotrexate-associated lymphoproliferative disorder and tuberculous meningitis demonstrating the definitive role of immunosuppression. Simultaneous appearance of methotrexate-associated lymphoproliferative disorder and tuberculous meningitis demonstrating the definitive role of immunosuppression. Annals of hematology, 88, 6, 589-90 Annals of hematology, 88, 6, 589-90 Annals of hematology, 88, 6, 589-90 2009/06 英語 公開
Sumimasa Nagai, Masaki Toshima, Kazuya Sato, Masaki Mori, Tadashi Nagai, Kazuo Muroi, Keiya Ozawa Sumimasa Nagai, Masaki Toshima, Kazuya Sato, Masaki Mori, Tadashi Nagai, Kazuo Muroi, Keiya Ozawa Sumimasa Nagai, Masaki Toshima, Kazuya Sato, Masaki Mori, Tadashi Nagai, Kazuo Muroi, Keiya Ozawa Maintenance and preemptive therapy with ganciclovir for cytomegalovirus colitis with extremely high antigenemia in adult T-cell leukemia. Maintenance and preemptive therapy with ganciclovir for cytomegalovirus colitis with extremely high antigenemia in adult T-cell leukemia. Maintenance and preemptive therapy with ganciclovir for cytomegalovirus colitis with extremely high antigenemia in adult T-cell leukemia. International journal of hematology, 89, 2, 249-250 International journal of hematology, 89, 2, 249-250 International journal of hematology, 89, 2, 249-250 2009/03 英語 公開
Sumimasa Nagai, Takashi Asai, Takuro Watanabe, Kumi Oshima, Akira Hangaishi, Yoshinobu Kanda, Toru Motokura, Shigeru Chiba, Shigeki Aoki, Kuni Ohtomo, Mineo Kurokawa Sumimasa Nagai, Takashi Asai, Takuro Watanabe, Kumi Oshima, Akira Hangaishi, Yoshinobu Kanda, Toru Motokura, Shigeru Chiba, Shigeki Aoki, Kuni Ohtomo, Mineo Kurokawa Sumimasa Nagai, Takashi Asai, Takuro Watanabe, Kumi Oshima, Akira Hangaishi, Yoshinobu Kanda, Toru Motokura, Shigeru Chiba, Shigeki Aoki, Kuni Ohtomo, Mineo Kurokawa Simultaneous appearance of central nervous system relapse and subarachnoid hemorrhage during the treatment for acute promyelocytic leukemia. Simultaneous appearance of central nervous system relapse and subarachnoid hemorrhage during the treatment for acute promyelocytic leukemia. Simultaneous appearance of central nervous system relapse and subarachnoid hemorrhage during the treatment for acute promyelocytic leukemia. Annals of hematology, 87, 7, 593-5 Annals of hematology, 87, 7, 593-5 Annals of hematology, 87, 7, 593-5 2008/07 英語 公開
Keisuke Kataoka, Koji Izutsu, Sumimasa Nagai, Akira Hangaishi, Toru Motokura, Tsuyoshi Takahashi, Mineo Kurokawa Keisuke Kataoka, Koji Izutsu, Sumimasa Nagai, Akira Hangaishi, Toru Motokura, Tsuyoshi Takahashi, Mineo Kurokawa Keisuke Kataoka, Koji Izutsu, Sumimasa Nagai, Akira Hangaishi, Toru Motokura, Tsuyoshi Takahashi, Mineo Kurokawa Elevated serum levels of soluble interleukin-2 receptor in chronic eosinophilic leukemia/hypereosinophilic syndrome with FIP1L1-PDGFR alpha fusion gene. Elevated serum levels of soluble interleukin-2 receptor in chronic eosinophilic leukemia/hypereosinophilic syndrome with FIP1L1-PDGFR alpha fusion gene. Elevated serum levels of soluble interleukin-2 receptor in chronic eosinophilic leukemia/hypereosinophilic syndrome with FIP1L1-PDGFR alpha fusion gene. International journal of hematology, 87, 4, 440-441 International journal of hematology, 87, 4, 440-441 International journal of hematology, 87, 4, 440-441 2008/05 英語 公開
Sumimasa Nagai, Motoshi Ichikawa, Tsuyoshi Takahashi, Hiroyuki Sato, Hiromitsu Yokota, Kumi Oshima, Koji Izutsu, Akira Hangaishi, Yoshinobu Kanda, Toru Motokura, Shigeru Chiba, Yutaka Yatomi, Mineo Kurokawa Sumimasa Nagai, Motoshi Ichikawa, Tsuyoshi Takahashi, Hiroyuki Sato, Hiromitsu Yokota, Kumi Oshima, Koji Izutsu, Akira Hangaishi, Yoshinobu Kanda, Toru Motokura, Shigeru Chiba, Yutaka Yatomi, Mineo Kurokawa Sumimasa Nagai, Motoshi Ichikawa, Tsuyoshi Takahashi, Hiroyuki Sato, Hiromitsu Yokota, Kumi Oshima, Koji Izutsu, Akira Hangaishi, Yoshinobu Kanda, Toru Motokura, Shigeru Chiba, Yutaka Yatomi, Mineo Kurokawa The origin of neoplastic mast cells in systemic mastocytosis with AML1/ETO-positive acute myeloid leukemia. The origin of neoplastic mast cells in systemic mastocytosis with AML1/ETO-positive acute myeloid leukemia. The origin of neoplastic mast cells in systemic mastocytosis with AML1/ETO-positive acute myeloid leukemia. Experimental hematology, 35, 11, 1747-52 Experimental hematology, 35, 11, 1747-52 Experimental hematology, 35, 11, 1747-52 2007/11 英語 公開
Kumi Oshima, Yoshinobu Kanda, Yuki Asano-Mori, Nahoko Nishimoto, Shunya Arai, Sumimasa Nagai, Hiroyuki Sato, Takuro Watanabe, Noriko Hosoya, Koji Izutsu, Takashi Asai, Akira Hangaishi, Toru Motokura, Shigeru Chiba, Mineo Kurokawa Kumi Oshima, Yoshinobu Kanda, Yuki Asano-Mori, Nahoko Nishimoto, Shunya Arai, Sumimasa Nagai, Hiroyuki Sato, Takuro Watanabe, Noriko Hosoya, Koji Izutsu, Takashi Asai, Akira Hangaishi, Toru Motokura, Shigeru Chiba, Mineo Kurokawa Kumi Oshima, Yoshinobu Kanda, Yuki Asano-Mori, Nahoko Nishimoto, Shunya Arai, Sumimasa Nagai, Hiroyuki Sato, Takuro Watanabe, Noriko Hosoya, Koji Izutsu, Takashi Asai, Akira Hangaishi, Toru Motokura, Shigeru Chiba, Mineo Kurokawa Presumptive treatment strategy for aspergillosis in allogeneic haematopoietic stem cell transplant recipients. Presumptive treatment strategy for aspergillosis in allogeneic haematopoietic stem cell transplant recipients. Presumptive treatment strategy for aspergillosis in allogeneic haematopoietic stem cell transplant recipients. The Journal of antimicrobial chemotherapy, 60, 2, 350-5 The Journal of antimicrobial chemotherapy, 60, 2, 350-5 The Journal of antimicrobial chemotherapy, 60, 2, 350-5 2007/08 英語 公開

  • <<
  • >>
  • 表示
タイトル言語:
Misc
著者 著者(日本語) 著者(英語) タイトル タイトル(日本語) タイトル(英語) 書誌情報等 書誌情報等(日本語) 書誌情報等(英語) 出版年月 査読の有無 記述言語 掲載種別 公開
永井 純正 永井 純正 新医薬品等の承認審査制度、行政 新医薬品等の承認審査制度、行政 CRCテキストブック第4版, 78-84 CRCテキストブック第4版, 78-84 , 78-84 2021/03 日本語 公開
永井 純正 永井 純正 がん治療のレギュラトリーサイエンス がん治療のレギュラトリーサイエンス 腫瘍内科, 26, 6, 677-684 腫瘍内科, 26, 6, 677-684 , 26, 6, 677-684 2020/12 日本語 公開
永井 純正 永井 純正 遺伝子パネル検査によって変わる今後の医療と医薬品開発 国内承認品目の審査報告書を読み解いて学ぶこと 遺伝子パネル検査によって変わる今後の医療と医薬品開発 国内承認品目の審査報告書を読み解いて学ぶこと Pharm Stage, 20, 6, 17-21 Pharm Stage, 20, 6, 17-21 , 20, 6, 17-21 2020/09 日本語 公開
永井 純正 永井 純正 血液悪性腫瘍に対する治療薬薬事承認の現状 血液悪性腫瘍に対する治療薬薬事承認の現状 臨床血液, 61, 5, 437-444 臨床血液, 61, 5, 437-444 , 61, 5, 437-444 2020/05 日本語 公開
永井 純正 永井 純正 新薬承認における日米の違い 新薬承認における日米の違い 内科 = Internal medicine : 臨床雑誌, 121, 3, 521-527 内科 = Internal medicine : 臨床雑誌, 121, 3, 521-527 , 121, 3, 521-527 2018/03 日本語 公開
永井 純正 永井 純正 抗腫瘍薬とコンパニオン診断薬の薬事規制に関する国際比較 抗腫瘍薬とコンパニオン診断薬の薬事規制に関する国際比較 International comparison of regulations on oncologic drugs and companion diagnostics 血液内科 = Hematology, 75, 1, 111-116 血液内科 = Hematology, 75, 1, 111-116 , 75, 1, 111-116 2017/07 日本語 公開
永井 純正 永井 純正 ゲノム編集によるAIDS・血液疾患の治療 (今月の臨床 万能幹細胞・幹細胞とゲノム編集 : 再生医療の進歩が医療を変える) -- (ES細胞・iPS細胞の臨床応用) ゲノム編集によるAIDS・血液疾患の治療 (今月の臨床 万能幹細胞・幹細胞とゲノム編集 : 再生医療の進歩が医療を変える) -- (ES細胞・iPS細胞の臨床応用) 臨床婦人科産科, 71, 5, 425-431 臨床婦人科産科, 71, 5, 425-431 , 71, 5, 425-431 2017/05 日本語 公開
永井 純正 永井 純正 コンパニオン診断薬と薬事規制 コンパニオン診断薬と薬事規制 Regulations on companion diagnostics 腫瘍内科 = Clinical oncology, 19, 4, 495-500 腫瘍内科 = Clinical oncology, 19, 4, 495-500 , 19, 4, 495-500 2017/04 日本語 公開
永井 純正 永井 純正 次世代シークエンサーやリキッドバイオプシー等を用いたコンパニオン診断薬の承認のあり方 (第21回 抗悪性腫瘍薬開発フォーラム『抗がん剤創薬に向けての次世代テクノロジーの展開 : 基礎から承認まで』) 次世代シークエンサーやリキッドバイオプシー等を用いたコンパニオン診断薬の承認のあり方 (第21回 抗悪性腫瘍薬開発フォーラム『抗がん剤創薬に向けての次世代テクノロジーの展開 : 基礎から承認まで』) Marketing authorization of companion diagnostics using next generation sequencing or liquid biopsies 腫瘍内科 = Clinical oncology, 18, 5, 535-540 腫瘍内科 = Clinical oncology, 18, 5, 535-540 , 18, 5, 535-540 2016/11 日本語 公開
永井 純正 永井 純正 医薬品の開発および評価における留意点 (特集 個別化医療とコンパニオン診断薬を取り巻く現状と問題点) 医薬品の開発および評価における留意点 (特集 個別化医療とコンパニオン診断薬を取り巻く現状と問題点) 医薬ジャーナル, 51, 8, 65-69 医薬ジャーナル, 51, 8, 65-69 , 51, 8, 65-69 2015/08 日本語 公開
永井 純正 永井 純正 コンパニオン診断薬を用いた抗がん剤の開発および評価における留意点 (第18回 抗悪性腫瘍薬開発フォーラム『次世代テクノロジーは抗がん剤開発に何をもたらすか? : 分子生物学的臨床開発基盤構築に向けて』) コンパニオン診断薬を用いた抗がん剤の開発および評価における留意点 (第18回 抗悪性腫瘍薬開発フォーラム『次世代テクノロジーは抗がん剤開発に何をもたらすか? : 分子生物学的臨床開発基盤構築に向けて』) Points to consider in development and evaluation of oncologic drugs with companion diagnostics 腫瘍内科 = Clinical oncology, 15, 5, 519-523 腫瘍内科 = Clinical oncology, 15, 5, 519-523 , 15, 5, 519-523 2015/05 日本語 公開
永井 純正 永井 純正 産業と行政 日本および欧米におけるコンパニオン診断薬の規制の現状および今後の展望 産業と行政 日本および欧米におけるコンパニオン診断薬の規制の現状および今後の展望 バイオサイエンスとインダストリー, 73, 5, 408-411 バイオサイエンスとインダストリー, 73, 5, 408-411 , 73, 5, 408-411 2015 日本語 公開
永井 純正 永井 純正 抗悪性腫瘍薬におけるコンパニオン診断薬の開発・審査の現状 抗悪性腫瘍薬におけるコンパニオン診断薬の開発・審査の現状 The present situation of development and regulatory review of marketing authorization of companion diagnostics in oncology Pharm stage, 14, 8, 1-3 Pharm stage, 14, 8, 1-3 Pharm stage, 14, 8, 1-3 2014/11 日本語 公開
永井 純正 永井 純正 血液腫瘍に対する新薬開発と規制・審査当局の役割 (特集 血液腫瘍に対する臨床試験のinfrastructure : 現状の問題点と今後の方向性) 血液腫瘍に対する新薬開発と規制・審査当局の役割 (特集 血液腫瘍に対する臨床試験のinfrastructure : 現状の問題点と今後の方向性) The role of regulatory agencies in the development of new drugs for hematologic malignancy 血液内科, 69, 1, 66-72 血液内科, 69, 1, 66-72 , 69, 1, 66-72 2014/07 日本語 公開
永井 純正 永井 純正 APLの治療標的解析の進歩 (特集 分子病態からみた血液疾患診療の進歩) APLの治療標的解析の進歩 (特集 分子病態からみた血液疾患診療の進歩) The progress of the therapeutic target analysis in acute promyelocytic leukemia 血液内科, 62, 4, 423-428 血液内科, 62, 4, 423-428 , 62, 4, 423-428 2011/04 日本語 公開
永井 純正 永井 純正 急性前骨髄球性白血病における微小残存病変のモニターとその意義 急性前骨髄球性白血病における微小残存病変のモニターとその意義 Monitoring of minimal residual disease in acute promyelocytic leukemia 血液・腫瘍科, 60, 3, 356-360 血液・腫瘍科, 60, 3, 356-360 , 60, 3, 356-360 2010/03 日本語 公開
永井 純正 永井 純正 三酸化ヒ素によるPML-RARαの不活化機構 三酸化ヒ素によるPML-RARαの不活化機構 Degradation of PML-RARα induced by arsenic trioxide 血液・腫瘍科, 58, 1, 130-134 血液・腫瘍科, 58, 1, 130-134 , 58, 1, 130-134 2009/01 日本語 公開

  • <<
  • >>
  • 表示
タイトル言語: